德琪医药-B：希维奥 在香港获批用于治疗多发性骨髓瘤及弥漫大B细胞淋巴瘤两种新增适应症

Core Viewpoint - The Hong Kong Special Administrative Region Government's Department of Health has approved two supplemental new drug applications (sNDA) for the drug Xivio (Selinexor) [1] Group 1: Drug Approvals - Xivio is approved for use in combination with Bortezomib and Dexamethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy [1] - Xivio is also approved as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL), specifically for those who have received at least two lines of systemic therapy and are not candidates for hematopoietic stem cell transplantation due to follicular lymphoma [1]